Cite
MLA Citation
Philip J Mease et al.. “Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.” Annals of the rheumatic diseases, vol. 81, no. 6, 2022, pp. 815–822. http://access.bl.uk/ark:/81055/vdc_100154267557.0x000023